GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (FRA:2HA) » Definitions » Float Percentage Of Total Shares Outstanding

Spero Therapeutics (FRA:2HA) Float Percentage Of Total Shares Outstanding : 82.77% (As of May. 14, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Spero Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Spero Therapeutics's float shares is 46.28 Mil. Spero Therapeutics's total shares outstanding is 55.91 Mil. Spero Therapeutics's float percentage of total shares outstanding is 82.77%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Spero Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Spero Therapeutics's Institutional Ownership is 6.40%.

Spero Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Spero Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=46.28/55.91
=82.77%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (FRA:2HA) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
PVCT BLUE ATNM RVPH HOWL AKTX CAMP HSTC IRD RNTX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
SPRO:USA
Address
675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Website
https://www.sperotherapeutics.com
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Headlines

No Headlines